Sector: Health Care
Director information for ORASURE TECHNOLOGIES INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Carrie Eglinton Manner | President and CEO, OraSure Technologies, Inc.; President and Chief Executive Officer | 52 | ["Extensive leadership experience in the healthcare industry","Proven track record of driving innovation","Scaling complex diagnostic businesses","Delivering strategic growth and transformation across global organizations","Launching and commercializing innovative products and technologies","Integrating acquisitions and building operations excellence","Operational insight for long-term growth strategy and capital allocation"] | [] | 2026 |
| David J. Shulkin, M.D. | [] | [] | 2026 | ||
| John D. Bertrand | Former Chief Executive Officer, Digital Diagnostics; Independent Director | 42 | ["Healthcare technology executive with more than a decade of experience driving artificial intelligence-enabled innovation in diagnostics","Expertise at the intersection of digital health, clinical workflows, and commercial strategy","Leadership in developing, commercializing, and implementing diagnostic solutions","Chief Executive Officer at Digital Diagnostics, transforming the company from research-stage to a global commercial platform","Experience at Bain Capital and 8VC advising on investment and innovation initiatives in healthcare"] | ["Nominating and Corporate Governance"] | 2026 |
| John P. Kenny | Former Chief Executive Officer, Meridian Bioscience; Chair of the Board | 57 | ["Accomplished diagnostics industry executive with more than 30 years of commercial and operational leadership experience","Oversaw the development, manufacturing and commercialization of innovative diagnostic products at Meridian Bioscience","Led a comprehensive operational turnaround at Meridian Bioscience","Built capabilities in marketing, product launches, portfolio planning, lifecycle management, new product development and mergers and acquisitions","Extensive public and private board experience in the diagnostics sector"] | ["Compensation"] | 2026 |
| Lelio Marmora | Former Executive Director, Unitaid | 59 | ["Global health sector executive with extensive experience leading large-scale investment portfolios and organizational transformations across more than 100 countries","President and Chief Executive Officer of The Management Lab","Chief Executive Officer of Unitaid, overseeing a $1.5 billion portfolio","Senior leadership positions at the Global Fund to Fight AIDS, Tuberculosis and Malaria","Director, World Bank Programs at Argentina Ministry of Industry"] | ["Nominating and Corporate Governance Committee","Audit","Nominating and Corporate Governance"] | 2026 |
| Mara G. Aspinall | [] | [] | 2026 | ||
| Nancy J. Gagliano, M.D. | Managing Director, Granite Healthcare Advisors; Independent Director | 66 | ["executive leader of the National Institute of Health's RADx Tech program","overseeing large federally funded diagnostic initiatives","developing key clinical programs at CVS Health and MinuteClinic","providing strategic guidance as Managing Director at Granite Healthcare Advisors","healthcare consulting services at Culbert Healthcare Solutions"] | ["Nominating and Corporate Governance Committee","Compensation","Nominating and Corporate Governance"] | 2026 |
| Robert W. McMahon | Senior Vice President and Chief Financial Officer, West Pharmaceutical Services; Independent Director | 57 | ["Accomplished healthcare finance and business executive","Experience in disciplined capital allocation and operational execution","Chief Financial Officer at West Pharmaceutical Services","CFO at Agilent Technologies","Oversaw finance and IT teams at Hologic","Financial transformation leadership"] | ["C","Audit (Chair)"] | 2026 |
| Steven K. Boyd | Former Partner, Camber Capital Management; Independent Director | 44 | ["Seasoned investor with over two decades of public markets experience across the healthcare industry","Track record of successfully identifying value creation opportunities that deliver long-term shareholder growth","Deep sector knowledge, analytical rigor, and financial expertise","Experience at Camber Capital Management, growing assets under management from around $300 million to nearly $3 billion","Identified and oversaw execution of strategic equity investments across various industries","Investment banking focus on global healthcare with expertise in M&A, strategic growth, and capital markets"] | ["AC","CC","Nominating and Corporate Governance Committee","Audit","Compensation Committee"] | 2026 |
